These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 15201935)

  • 1. [Biological modulation of IL-1 activity: role and development of its natural inhibitor IL-1Ra].
    Dayer JM
    Reumatismo; 2004; 56(1 Suppl 1):3-8. PubMed ID: 15201935
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evidence for the biological modulation of IL-1 activity: the role of IL-1Ra.
    Dayer JM
    Clin Exp Rheumatol; 2002; 20(5 Suppl 27):S14-20. PubMed ID: 14989424
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Single and combined inhibition of tumor necrosis factor, interleukin-1, and RANKL pathways in tumor necrosis factor-induced arthritis: effects on synovial inflammation, bone erosion, and cartilage destruction.
    Zwerina J; Hayer S; Tohidast-Akrad M; Bergmeister H; Redlich K; Feige U; Dunstan C; Kollias G; Steiner G; Smolen J; Schett G
    Arthritis Rheum; 2004 Jan; 50(1):277-90. PubMed ID: 14730626
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Modulation of osteoclast-activating factor activity of multiple myeloma bone marrow cells by different interleukin-1 inhibitors.
    Torcia M; Lucibello M; Vannier E; Fabiani S; Miliani A; Guidi G; Spada O; Dower SK; Sims JE; Shaw AR; Dinarello CA; Garaci E; Cozzolino F
    Exp Hematol; 1996 Jul; 24(8):868-74. PubMed ID: 8690044
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Interleukin-1 and tumor necrosis factor and their naturally occurring antagonists during hemodialysis.
    Dinarello CA
    Kidney Int Suppl; 1992 Oct; 38():S68-77. PubMed ID: 1328757
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Interleukin-1 and interleukin-1 receptor antagonist.
    Dinarello CA
    Nutrition; 1995; 11(5 Suppl):492-4. PubMed ID: 8748206
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Suppression of experimental osteoarthritis by adenovirus-mediated double gene transfer.
    Wang HJ; Yu CL; Kishi H; Motoki K; Mao ZB; Muraguchi A
    Chin Med J (Engl); 2006 Aug; 119(16):1365-73. PubMed ID: 16934183
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Activation of the peroxisome proliferator-activated receptor alpha pathway potentiates interleukin-1 receptor antagonist production in cytokine-treated chondrocytes.
    François M; Richette P; Tsagris L; Fitting C; Lemay C; Benallaoua M; Tahiri K; Corvol MT
    Arthritis Rheum; 2006 Apr; 54(4):1233-45. PubMed ID: 16572457
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The pivotal role of interleukin-1 in the clinical manifestations of rheumatoid arthritis.
    Dayer JM
    Rheumatology (Oxford); 2003 May; 42 Suppl 2():ii3-10. PubMed ID: 12817089
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Role of interleukin-1 and tumor necrosis factor alpha in matrix degradation of human osteoarthritic cartilage.
    Kobayashi M; Squires GR; Mousa A; Tanzer M; Zukor DJ; Antoniou J; Feige U; Poole AR
    Arthritis Rheum; 2005 Jan; 52(1):128-35. PubMed ID: 15641080
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Involvement of tumor necrosis factor-alpha in the development of T cell-dependent aortitis in interleukin-1 receptor antagonist-deficient mice.
    Matsuki T; Isoda K; Horai R; Nakajima A; Aizawa Y; Suzuki K; Ohsuzu F; Iwakura Y
    Circulation; 2005 Aug; 112(9):1323-31. PubMed ID: 16129814
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Soluble interleukin-1 receptor accessory protein ameliorates collagen-induced arthritis by a different mode of action from that of interleukin-1 receptor antagonist.
    Smeets RL; Joosten LA; Arntz OJ; Bennink MB; Takahashi N; Carlsen H; Martin MU; van den Berg WB; van de Loo FA
    Arthritis Rheum; 2005 Jul; 52(7):2202-11. PubMed ID: 15986350
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Interleukin-1 and tumor necrosis factor antagonists attenuate ethanol-induced inhibition of bone formation in a rat model of distraction osteogenesis.
    Perrien DS; Brown EC; Fletcher TW; Irby DJ; Aronson J; Gao GG; Skinner RA; Hogue WR; Feige U; Suva LJ; Ronis MJ; Badger TM; Lumpkin CK
    J Pharmacol Exp Ther; 2002 Dec; 303(3):904-8. PubMed ID: 12438508
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Role of matrix metalloproteinase-3 in joint destruction in rheumatoid arthritis].
    Sugiyama E
    Clin Calcium; 2007 Apr; 17(4):528-34. PubMed ID: 17404481
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Updated consensus statement on biological agents, specifically tumour necrosis factor {alpha} (TNF{alpha}) blocking agents and interleukin-1 receptor antagonist (IL-1ra), for the treatment of rheumatic diseases, 2005.
    Furst DE; Breedveld FC; Kalden JR; Smolen JS; Burmester GR; Bijlsma JW; Dougados M; Emery P; Keystone EC; Klareskog L; Mease PJ
    Ann Rheum Dis; 2005 Nov; 64 Suppl 4(Suppl 4):iv2-14. PubMed ID: 16239380
    [No Abstract]   [Full Text] [Related]  

  • 16. The combined effects of anti-TNFalpha antibody and IL-1 receptor antagonist in human rheumatoid arthritis synovial membrane.
    Hosaka K; Ryu J; Saitoh S; Ishii T; Kuroda K; Shimizu K
    Cytokine; 2005 Dec; 32(6):263-9. PubMed ID: 16406555
    [TBL] [Abstract][Full Text] [Related]  

  • 17. RANKL-stimulated osteoclast-like cell formation in vitro is partially dependent on endogenous interleukin-1 production.
    Lee SK; Gardner AE; Kalinowski JF; Jastrzebski SL; Lorenzo JA
    Bone; 2006 May; 38(5):678-85. PubMed ID: 16309985
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Therapeutic strategies to reduce IL-1 activity in treating local and systemic inflammation.
    Dinarello CA
    Curr Opin Pharmacol; 2004 Aug; 4(4):378-85. PubMed ID: 15251132
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anti-inflammatory effects of hepatocyte growth factor: induction of interleukin-1 receptor antagonist.
    Molnar C; Garcia-Trevijano ER; Ludwiczek O; Talabot D; Kaser A; Mato JM; Fritsche G; Weiss G; Gabay C; Avila MA; Tilg H
    Eur Cytokine Netw; 2004; 15(4):303-11. PubMed ID: 15627638
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Interleukin-1 receptor antagonist intervenes in signaling between different types of synoviocytes in rats with adjuvant arthritis.
    Zheng YQ; Wei W; Dai M; Zhu L; Jia XY; Wang Y
    Acta Pharmacol Sin; 2006 Jan; 27(1):111-8. PubMed ID: 16364217
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.